Endologix (NASDAQ:ELGX) has an appealing product pipeline in the field of Endovascular aortic repair, or EVAR. Its innovative products such as AFX, Nellix, and Ventana have the potential to grow its EVAR segment substantially. According to Endologix, around 63,000 abdominal aortic aneurysm, or AAA repairs were done in 2012; out of those, 75% were EVAR procedures and 25% were open surgery procedures. This depicts the dominance of EVAR in treating AAA and thus opens a significant opportunity for Endologix to excel in the field of EVAR. Further, it has an impressive historical (2008-2012) track record of driving consistent 20% plus revenue growth. Over the past three years, it has achieved a remarkable CAGR of 26%.
I expect it...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|